<DOC>
	<DOCNO>NCT01456689</DOCNO>
	<brief_summary>The primary purpose dose escalation study estimate maximum tolerate dose ( MTD ) and/or recommend dose expansion ( RDE ) LGH447 single agent administer orally daily adult patient Multiple Myeloma ( MM ) .</brief_summary>
	<brief_title>A Study Oral LGH447 Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma relapse and/or refractory curative option exists . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . During dose expansion part study patient must measurable disease define least 1 follow 2 measurement : Serum Mprotein ≥ 0.5 g/dL Urine Mprotein ≥ 200 mg/24 hour Serum free light chain ( FLC ) &gt; 100 mg/L involve FLC Patients currently receive treatment medication meet one follow criterion discontinue least one week prior start treatment LGH447 : Strong inhibitor inducer CYP3A4 CYP3A4 substrates narrow therapeutic index Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MM</keyword>
</DOC>